PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best-validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much-needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy, and a broad array of pain models.
In PRISM 2, we are involved in the preclinical back-translation and biological validation (WP4), specifically validating the association of social deficit with EEG readouts and the back-translation of the patient cluster phenotype to a disease-related preclinical model.